UBS Group’s Innate Pharma IPHA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $10.8K | Sell |
5,957
-3,044
| -34% | -$5.52K | ﹤0.01% | 7499 |
|
|
2025
Q1 | $16K | Buy |
9,001
+5,491
| +156% | +$9.77K | ﹤0.01% | 7063 |
|
|
2024
Q4 | $6.46K | Sell |
3,510
-4,898
| -58% | -$9.01K | ﹤0.01% | 7322 |
|
|
2024
Q3 | $19.3K | Buy |
8,408
+8,111
| +2,731% | +$18.6K | ﹤0.01% | 6190 |
|
|
2024
Q2 | $576 | Buy |
297
+87
| +41% | +$169 | ﹤0.01% | 7693 |
|
|
2024
Q1 | $604 | Buy |
210
+64
| +44% | +$184 | ﹤0.01% | 7280 |
|
|
2023
Q4 | $409 | Hold |
146
| – | – | ﹤0.01% | 7460 |
|
|
2023
Q3 | $369 | Hold |
146
| – | – | ﹤0.01% | 7398 |
|
|
2023
Q2 | $449 | Sell |
146
-1,113
| -88% | -$3.42K | ﹤0.01% | 7146 |
|
|
2023
Q1 | $3.59K | Buy |
1,259
+1,113
| +762% | +$3.17K | ﹤0.01% | 7199 |
|
|
2022
Q4 | $545 | Sell |
146
-4,359
| -97% | -$16.3K | ﹤0.01% | 8938 |
|
|
2022
Q3 | $9K | Buy |
4,505
+1,549
| +52% | +$3.1K | ﹤0.01% | 7476 |
|
|
2022
Q2 | $8K | Buy |
+2,956
| New | +$8K | ﹤0.01% | 7274 |
|